International Journal of Molecular Science: Published on January 2024

Gastroesophageal reflux disease (GERD) is a common disease of the digestive system with a worldwide prevalence of 8 to 33% and is characterized by the persistent reflux of gastroduodenal content that ascends through the esophageal tube, causing esophageal and extraesophageal signs and symptoms.

In addition to clinical symptoms such as acid regurgitation, heartburn, dental erosions, halitosis, chronic cough, asthma, and recurrent pneumonia, GERD also has negative psychological effects on the patient, being responsible for large public health expenditures.

TAKE HOME MESSAGE

This systematic review and meta-analysis evaluated the efficacy of dexlansoprazole (a proton pump inhibitor-PPI) in resolving heartburn, reflux, and other symptoms and complications resulting from gastroesophageal reflux disease (GERD).

Dexlansoprazole outperformed the placebo and other PPIs in the resolution of heartburn and reflux symptoms in patients with GERD, with benefits during and after treatment, especially in those with moderate and severe symptoms.

The meta-analyses indicated that dexlansoprazole at doses of 30 and 60 mg had more 24 h heartburn-free days and nights compared to the placebo medications at improving symptoms of heartburn and reflux in symptomatic GERD patients, leading to improved sleep quality and a decreased symptom severity and impact on daily activities.

No difference was reported between dexlansoprazole at doses of 30 and 60 mg in heartburn-free nights.

This review confirms the therapeutic effect of dexlansoprazole (placebo-controlled) and its improvements in GERD symptoms compared to another PPI.

Conclusions

The evidence points out that dexlansoprazole has a satisfactory effect on the resolution of heartburn and reflux symptoms in patients with GERD and its erosive complications, with benefits during and after treatment, in different dosages, and, mainly, in those with moderate and severe symptoms.